Maxim Group Downgrades Bionano Genomics to Hold
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Jason McCarthy has downgraded Bionano Genomics (NASDAQ:BNGO) from Buy to Hold, indicating a shift in the firm's outlook on the company's stock.
November 13, 2023 | 12:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Bionano Genomics was downgraded by Maxim Group from Buy to Hold, which may lead to a negative perception among investors and could impact the stock's performance in the short term.
Downgrades by analysts can often lead to a decrease in investor confidence and a potential drop in stock price as the market adjusts to the new rating. Given that this is a direct downgrade from Buy to Hold, it suggests a significant change in the analyst's view on the stock, which could influence investor sentiment and trading behavior.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100